Analysis on Market Share of Domestic Pediatric Gastrointestinal Drugs in the First Half of 2016 – MAMIAI Topped the List


January 18, - this article will analyze conditions of retail gastrointestinal tract drugs in the first half of 2016 according to the Data of 22 Cities (unless otherwise provided, the data in this article are the aggregated data of the said 22 cities) in Chinese Drug Retailers Competition Pattern Database from MENET.

(Note: the said 22 cities are Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Wuhan, Chongqing, Qingdao, Shenzhen, Changchun, Ningbo, Changsha, Xi'an, Harbin, Zhengzhou, Shijiazhuang, Wuxi, Yangzhou, Suzhou, Nanchang)

Adult drugs dominate the market and pediatric drugs have a better growth

The changes in current lifestyle lead to more and more patients with gastrointestinal diseases, therefore, the gastrointestinal drug market is on the rise, among which, adult drugs dominate the market, accounting for more than 90%. The proportion for pediatric drugs is smaller than adults, but has a better growth. It has increased to 7.51% in 2015 from 1.27% in 2013 and its growth rate is preliminarily predicted to exceed 10% in 2016.

Due to the imperfect development of digestive system, weak body resistance and insufficient self-care of children, morbidity of gastrointestinal diseases is higher than adults. With the full liberalization of two-child policy, the number of Chinese children will gradually increase, bringing a huge development space for pediatric drugs.

Different dosage forms for different groups of people

The common dosage forms for gastrointestinal drugs are tablet, capsule, solution, powder, granules, pills, etc. Different dosage forms have their features to meet the requirements of different groups of people. The tablet has the highest proportion in retail adult gastrointestinal drugs, accounting for 38.58% in the first half of 2016. It is favored by consumers because it is convenient to take, carry and transport with stable quality and accurate dosage.

Different from adult drugs, pediatric drugs should fully consider the safety, pesticide effect, bioavailability, swallowing difficulty, taking conveniences, taste, flavor and other factors. Because they are convenient to take and easy to absorb with stable pesticide effect and good taste, powder and granules become the dominant dosage forms in pediatric drug.

In the first half of 2016, power and granules of pediatric gastrointestinal drugs account for 39.10% market share, taking an absolutely dominant position. Domestic pharmaceutical companies have paid less attention to the innovation of types of pediatric gastrointestinal drugs, but to dosage forms. Powder and granules are suitable for children to take and will get more policy supports and competitive advantages, and its market share in pediatric drugs will continue to rise.

In addition, it is worth noting that emplastrum is completely suitable for pediatric drugs, compared with other innovative dosage forms. Due to its convenience, safety and quick effects, emplastrum owns absolute competitive advantages in pediatric drug market with great response. According to the statistics, more than 1 billion children have used emplastrum. All of them lead to a significant difference in the market share between adult emplastrum and pediatric emplastrum. According to the figure, pediatric emplastrum accounts for 14.33%, while adult emplastrum accounts for only 0.14%.

Pediatric drug market has a high concentration, and digestant brands have significant advantages.

Gastrointestinal drug is one of the main types in the retail pharmacy market and also an important field for many pharmaceutical companies. According to the statistic data of MENET, the total market share of top 10 adult gastrointestinal drug brands in 22 cities in the first half of 2016 is 25.82% with a lower concentration.

With the special features of fewer types and small specifications for pediatric drugs, competition in gastrointestinal drugs is fierce. The total market share of top 10 pediatric gastrointestinal drug brands in 22 cities in the first half of 2016 is 80.90% with a higher concentration.

According to the category involved of the Top 10 brands, adult gastrointestinal drugs have no obvious category features. Due to the higher morbidity of dyspepsia for children as the immature spleen and stomach, among the top 10 pediatric gastrointestinal drug brands, there are 8 brands make digestant, with the market share of 65.02%.

Among the 8 digestant brands, there are 2 brands for chemical drugs and 6 brands for Chinese patent drugs, which indicate that parents tend to Chinese patent drugs when selecting pediatric drugs. It is worth noting that the top brand in the list is "MAMIAI" of Beijing Hanmi Pharm., with the market share of 27.65%. In recent years, taking advantage of advertisements and doctor's prescriptions, "MAMIAI" has developed rapidly, and is deeply favored by parents, taking the first place in fewer pediatric gastrointestinal drugs.

Source of the article:
Analysis on Market Share of Domestic Pediatric Gastrointestinal Drugs in the First Half of 2016 – MAMIAI Topped the List  | PHARMNET